Statin use and risk of developing diabetes

Results from the diabetes prevention program

on behalf of the Diabetes Prevention Program(DPP) Research Group

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective Several clinical trials of cardiovascular disease prevention with statins have reported increased risk of type 2 diabetes (T2DM) with statin therapy. However, participants in these studies were at relatively low risk for diabetes. Further, diabetes was often based on selfreport and was not the primary outcome. It is unknown whether statins similarly modify diabetes risk in higher risk populations. Research design and methods During the Diabetes Prevention Program Outcomes Study (n=3234), the long-term follow-up to a randomized clinical trial of interventions to prevent T2DM, incident diabetes was assessed by annual 75 g oral glucose tolerance testing and semiannual fasting glucose. Lipid profile was measured annually, with statin treatment determined by a participant’s own physician outside of the protocol. Statin use was assessed at baseline and semiannual visits. Results At 10 years, the cumulative incidence of statin initiation prior to diabetes diagnosis was 33%–37% among the randomized treatment groups (p=0.36). Statin use was associated with greater diabetes risk irrespective of treatment group, with pooled HR (95% CI) for incident diabetes of 1.36 (1.17 to 1.58). This risk was not materially altered by adjustment for baseline diabetes risk factors and potential confounders related to indications for statin therapy. Conclusions In this population at high risk for diabetes, we observed significantly higher rates of diabetes with statin therapy in all three treatment groups. Confounding by indication for statin use does not appear to explain this relationship. The effect of statins to increase diabetes risk appears to extend to populations at high risk for diabetes.

Original languageEnglish (US)
Article numbere000438
JournalBMJ Open Diabetes Research and Care
Volume5
Issue number1
DOIs
StatePublished - Sep 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
Glucose Tolerance Test
Type 2 Diabetes Mellitus
Fasting
Research Design
Cardiovascular Diseases
Randomized Controlled Trials
Outcome Assessment (Health Care)
Clinical Trials

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Statin use and risk of developing diabetes : Results from the diabetes prevention program. / on behalf of the Diabetes Prevention Program(DPP) Research Group.

In: BMJ Open Diabetes Research and Care, Vol. 5, No. 1, e000438, 01.09.2017.

Research output: Contribution to journalArticle

on behalf of the Diabetes Prevention Program(DPP) Research Group. / Statin use and risk of developing diabetes : Results from the diabetes prevention program. In: BMJ Open Diabetes Research and Care. 2017 ; Vol. 5, No. 1.
@article{5181564aaaec43b0af9758294e65e19a,
title = "Statin use and risk of developing diabetes: Results from the diabetes prevention program",
abstract = "Objective Several clinical trials of cardiovascular disease prevention with statins have reported increased risk of type 2 diabetes (T2DM) with statin therapy. However, participants in these studies were at relatively low risk for diabetes. Further, diabetes was often based on selfreport and was not the primary outcome. It is unknown whether statins similarly modify diabetes risk in higher risk populations. Research design and methods During the Diabetes Prevention Program Outcomes Study (n=3234), the long-term follow-up to a randomized clinical trial of interventions to prevent T2DM, incident diabetes was assessed by annual 75 g oral glucose tolerance testing and semiannual fasting glucose. Lipid profile was measured annually, with statin treatment determined by a participant’s own physician outside of the protocol. Statin use was assessed at baseline and semiannual visits. Results At 10 years, the cumulative incidence of statin initiation prior to diabetes diagnosis was 33{\%}–37{\%} among the randomized treatment groups (p=0.36). Statin use was associated with greater diabetes risk irrespective of treatment group, with pooled HR (95{\%} CI) for incident diabetes of 1.36 (1.17 to 1.58). This risk was not materially altered by adjustment for baseline diabetes risk factors and potential confounders related to indications for statin therapy. Conclusions In this population at high risk for diabetes, we observed significantly higher rates of diabetes with statin therapy in all three treatment groups. Confounding by indication for statin use does not appear to explain this relationship. The effect of statins to increase diabetes risk appears to extend to populations at high risk for diabetes.",
author = "{on behalf of the Diabetes Prevention Program(DPP) Research Group} and Crandall, {Jill P.} and Kieren Mather and Rajpathak, {Swapnil N.} and Goldberg, {Ronald B.} and Karol Watson and Sandra Foo and Robert Ratner and Elizabeth Barrett-Connor and Marinella Temprosa",
year = "2017",
month = "9",
day = "1",
doi = "10.1136/bmjdrc-2017-000438",
language = "English (US)",
volume = "5",
journal = "BMJ Open Diabetes Research and Care",
issn = "2052-4897",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Statin use and risk of developing diabetes

T2 - Results from the diabetes prevention program

AU - on behalf of the Diabetes Prevention Program(DPP) Research Group

AU - Crandall, Jill P.

AU - Mather, Kieren

AU - Rajpathak, Swapnil N.

AU - Goldberg, Ronald B.

AU - Watson, Karol

AU - Foo, Sandra

AU - Ratner, Robert

AU - Barrett-Connor, Elizabeth

AU - Temprosa, Marinella

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective Several clinical trials of cardiovascular disease prevention with statins have reported increased risk of type 2 diabetes (T2DM) with statin therapy. However, participants in these studies were at relatively low risk for diabetes. Further, diabetes was often based on selfreport and was not the primary outcome. It is unknown whether statins similarly modify diabetes risk in higher risk populations. Research design and methods During the Diabetes Prevention Program Outcomes Study (n=3234), the long-term follow-up to a randomized clinical trial of interventions to prevent T2DM, incident diabetes was assessed by annual 75 g oral glucose tolerance testing and semiannual fasting glucose. Lipid profile was measured annually, with statin treatment determined by a participant’s own physician outside of the protocol. Statin use was assessed at baseline and semiannual visits. Results At 10 years, the cumulative incidence of statin initiation prior to diabetes diagnosis was 33%–37% among the randomized treatment groups (p=0.36). Statin use was associated with greater diabetes risk irrespective of treatment group, with pooled HR (95% CI) for incident diabetes of 1.36 (1.17 to 1.58). This risk was not materially altered by adjustment for baseline diabetes risk factors and potential confounders related to indications for statin therapy. Conclusions In this population at high risk for diabetes, we observed significantly higher rates of diabetes with statin therapy in all three treatment groups. Confounding by indication for statin use does not appear to explain this relationship. The effect of statins to increase diabetes risk appears to extend to populations at high risk for diabetes.

AB - Objective Several clinical trials of cardiovascular disease prevention with statins have reported increased risk of type 2 diabetes (T2DM) with statin therapy. However, participants in these studies were at relatively low risk for diabetes. Further, diabetes was often based on selfreport and was not the primary outcome. It is unknown whether statins similarly modify diabetes risk in higher risk populations. Research design and methods During the Diabetes Prevention Program Outcomes Study (n=3234), the long-term follow-up to a randomized clinical trial of interventions to prevent T2DM, incident diabetes was assessed by annual 75 g oral glucose tolerance testing and semiannual fasting glucose. Lipid profile was measured annually, with statin treatment determined by a participant’s own physician outside of the protocol. Statin use was assessed at baseline and semiannual visits. Results At 10 years, the cumulative incidence of statin initiation prior to diabetes diagnosis was 33%–37% among the randomized treatment groups (p=0.36). Statin use was associated with greater diabetes risk irrespective of treatment group, with pooled HR (95% CI) for incident diabetes of 1.36 (1.17 to 1.58). This risk was not materially altered by adjustment for baseline diabetes risk factors and potential confounders related to indications for statin therapy. Conclusions In this population at high risk for diabetes, we observed significantly higher rates of diabetes with statin therapy in all three treatment groups. Confounding by indication for statin use does not appear to explain this relationship. The effect of statins to increase diabetes risk appears to extend to populations at high risk for diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85031504318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031504318&partnerID=8YFLogxK

U2 - 10.1136/bmjdrc-2017-000438

DO - 10.1136/bmjdrc-2017-000438

M3 - Article

VL - 5

JO - BMJ Open Diabetes Research and Care

JF - BMJ Open Diabetes Research and Care

SN - 2052-4897

IS - 1

M1 - e000438

ER -